Characterization of two monoclonal antibodies directed against the 67 kDa high affinity laminin receptor and application for the study of breast carcinoma progression

S. Martignone, R. Pellegrini, E. Villa, N. N. Tandon, A. Mastroianni, E. Tagliabue, S. Ménard, Maria I. Colnaghi

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Two monoclonal antibodies (mAbs), designated MLuC5 and MLuC6, were produced against a human small cell lung carcinoma cell line. They were found to exhibit a superimposable reactivity on different cell lines and on platelets. Moreover, they both immunoprecipitated a 67 kDa molecule from the membrane of the reference target cells. Immunodepletion and cross-inhibition tests indicated that the two mAbs recognize two epitopes closely localized on the same molecule. The MLuC5 mAb was further characterized for its reactivity on platelets. Immunoprecipitation and ELISA assays demonstrate that this mAb recognizes the 67 kDa high afinity laminin receptor. MLuC5 reactivity was evaluated by immunohistochemistry on a variety of normal and tumor tissues, in particular breast specimens including normal epithelium, dysplastic lesions, in situ carcinomas, invasive primary carcinomas and distant metastases. The laminin receptor was found to be strongly expressed in 50% of the infiltrating carcinomas, whereas in situ carcinomas and benign lesions, as well as the normal mammary epithelium, were only weakly and focally positive. In metastatic lesions MLuC5 reactivity was only found in 11% of the samples tested, independently of the site of origin of the lesion.

Original languageEnglish
Pages (from-to)379-386
Number of pages8
JournalClinical & Experimental Metastasis
Volume10
Issue number6
DOIs
Publication statusPublished - Nov 1992

Fingerprint

Laminin Receptors
Carcinoma in Situ
Breast
Blood Platelets
Epithelium
Monoclonal Antibodies
Breast Neoplasms
Carcinoma
Cell Line
Small Cell Lung Carcinoma
Immunoprecipitation
Epitopes
Enzyme-Linked Immunosorbent Assay
Immunohistochemistry
Neoplasm Metastasis
Membranes
Neoplasms

Keywords

  • breast carcinoma
  • laminin receptor
  • monoclonal antibodies
  • prognosis
  • tumor marker

ASJC Scopus subject areas

  • Cancer Research

Cite this

Characterization of two monoclonal antibodies directed against the 67 kDa high affinity laminin receptor and application for the study of breast carcinoma progression. / Martignone, S.; Pellegrini, R.; Villa, E.; Tandon, N. N.; Mastroianni, A.; Tagliabue, E.; Ménard, S.; Colnaghi, Maria I.

In: Clinical & Experimental Metastasis, Vol. 10, No. 6, 11.1992, p. 379-386.

Research output: Contribution to journalArticle

Martignone, S. ; Pellegrini, R. ; Villa, E. ; Tandon, N. N. ; Mastroianni, A. ; Tagliabue, E. ; Ménard, S. ; Colnaghi, Maria I. / Characterization of two monoclonal antibodies directed against the 67 kDa high affinity laminin receptor and application for the study of breast carcinoma progression. In: Clinical & Experimental Metastasis. 1992 ; Vol. 10, No. 6. pp. 379-386.
@article{ebc5e9fdbbb54483ab80ec98067a3a94,
title = "Characterization of two monoclonal antibodies directed against the 67 kDa high affinity laminin receptor and application for the study of breast carcinoma progression",
abstract = "Two monoclonal antibodies (mAbs), designated MLuC5 and MLuC6, were produced against a human small cell lung carcinoma cell line. They were found to exhibit a superimposable reactivity on different cell lines and on platelets. Moreover, they both immunoprecipitated a 67 kDa molecule from the membrane of the reference target cells. Immunodepletion and cross-inhibition tests indicated that the two mAbs recognize two epitopes closely localized on the same molecule. The MLuC5 mAb was further characterized for its reactivity on platelets. Immunoprecipitation and ELISA assays demonstrate that this mAb recognizes the 67 kDa high afinity laminin receptor. MLuC5 reactivity was evaluated by immunohistochemistry on a variety of normal and tumor tissues, in particular breast specimens including normal epithelium, dysplastic lesions, in situ carcinomas, invasive primary carcinomas and distant metastases. The laminin receptor was found to be strongly expressed in 50{\%} of the infiltrating carcinomas, whereas in situ carcinomas and benign lesions, as well as the normal mammary epithelium, were only weakly and focally positive. In metastatic lesions MLuC5 reactivity was only found in 11{\%} of the samples tested, independently of the site of origin of the lesion.",
keywords = "breast carcinoma, laminin receptor, monoclonal antibodies, prognosis, tumor marker",
author = "S. Martignone and R. Pellegrini and E. Villa and Tandon, {N. N.} and A. Mastroianni and E. Tagliabue and S. M{\'e}nard and Colnaghi, {Maria I.}",
year = "1992",
month = "11",
doi = "10.1007/BF00133466",
language = "English",
volume = "10",
pages = "379--386",
journal = "Clinical and Experimental Metastasis",
issn = "0262-0898",
publisher = "Springer Netherlands",
number = "6",

}

TY - JOUR

T1 - Characterization of two monoclonal antibodies directed against the 67 kDa high affinity laminin receptor and application for the study of breast carcinoma progression

AU - Martignone, S.

AU - Pellegrini, R.

AU - Villa, E.

AU - Tandon, N. N.

AU - Mastroianni, A.

AU - Tagliabue, E.

AU - Ménard, S.

AU - Colnaghi, Maria I.

PY - 1992/11

Y1 - 1992/11

N2 - Two monoclonal antibodies (mAbs), designated MLuC5 and MLuC6, were produced against a human small cell lung carcinoma cell line. They were found to exhibit a superimposable reactivity on different cell lines and on platelets. Moreover, they both immunoprecipitated a 67 kDa molecule from the membrane of the reference target cells. Immunodepletion and cross-inhibition tests indicated that the two mAbs recognize two epitopes closely localized on the same molecule. The MLuC5 mAb was further characterized for its reactivity on platelets. Immunoprecipitation and ELISA assays demonstrate that this mAb recognizes the 67 kDa high afinity laminin receptor. MLuC5 reactivity was evaluated by immunohistochemistry on a variety of normal and tumor tissues, in particular breast specimens including normal epithelium, dysplastic lesions, in situ carcinomas, invasive primary carcinomas and distant metastases. The laminin receptor was found to be strongly expressed in 50% of the infiltrating carcinomas, whereas in situ carcinomas and benign lesions, as well as the normal mammary epithelium, were only weakly and focally positive. In metastatic lesions MLuC5 reactivity was only found in 11% of the samples tested, independently of the site of origin of the lesion.

AB - Two monoclonal antibodies (mAbs), designated MLuC5 and MLuC6, were produced against a human small cell lung carcinoma cell line. They were found to exhibit a superimposable reactivity on different cell lines and on platelets. Moreover, they both immunoprecipitated a 67 kDa molecule from the membrane of the reference target cells. Immunodepletion and cross-inhibition tests indicated that the two mAbs recognize two epitopes closely localized on the same molecule. The MLuC5 mAb was further characterized for its reactivity on platelets. Immunoprecipitation and ELISA assays demonstrate that this mAb recognizes the 67 kDa high afinity laminin receptor. MLuC5 reactivity was evaluated by immunohistochemistry on a variety of normal and tumor tissues, in particular breast specimens including normal epithelium, dysplastic lesions, in situ carcinomas, invasive primary carcinomas and distant metastases. The laminin receptor was found to be strongly expressed in 50% of the infiltrating carcinomas, whereas in situ carcinomas and benign lesions, as well as the normal mammary epithelium, were only weakly and focally positive. In metastatic lesions MLuC5 reactivity was only found in 11% of the samples tested, independently of the site of origin of the lesion.

KW - breast carcinoma

KW - laminin receptor

KW - monoclonal antibodies

KW - prognosis

KW - tumor marker

UR - http://www.scopus.com/inward/record.url?scp=0026499544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026499544&partnerID=8YFLogxK

U2 - 10.1007/BF00133466

DO - 10.1007/BF00133466

M3 - Article

C2 - 1333381

AN - SCOPUS:0026499544

VL - 10

SP - 379

EP - 386

JO - Clinical and Experimental Metastasis

JF - Clinical and Experimental Metastasis

SN - 0262-0898

IS - 6

ER -